Project ALS and Amylyx Enter Collaboration to Test AMX0035

Home
news
Project ALS and Amylyx Enter Collaboration to Test AMX0035

Project ALS and Amylyx Enter Collaboration to Test AMX0035

Amylyx closes a $ 5 million Series A Investment

Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis

Recent Posts

New ALS Association Partnership with ALS Investment Fund Targets $100 Million in New Funding for ALS Therapeutic Development
Amylyx Pharmaceuticals Announces AMX0035 Demonstrated Statistically Signiﬁcant Treatment Beneﬁt for People with ALS in the CENTAUR Trial
Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
Search for cure against the lethal disease ALS boosted by new investor
Orphazyme closes a €14 million Series B Extension

ROBERT BROWN

Scientific Advisory Board